Vanguard Group
MGRX icon

Vanguard Group’s Mangoceuticals MGRX Stock Holding History

Vanguard Group’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$362K Buy
489,532
+297,528
+155% +$483K ﹤0.01% 4004
2025
Q3 		$420K Buy
192,004
+9,391
+5% +$17.5K ﹤0.01% 3991
2025
Q2 		$278K Buy
+182,613
New +$343K ﹤0.01% 4033

Other funds holding MGRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return

Vanguard Group's MGRX Position: Q4 2025 in Review

Vanguard Group increased its Mangoceuticals (MGRX) stake by 155% in Q4 2025, buying an estimated $483K and bringing the position to 489,532 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #4004.

Vanguard Group first reported a position in MGRX in Q2 2025 and has held it in 3 quarters since. The position peaked at $420K in Q3 2025. 18 funds tracked by Wall St. Rank hold MGRX as of Q4 2025.

  • Vanguard Group held 489,532 shares of Mangoceuticals worth $362K as of Q4 2025.
  • Vanguard Group bought 297,528 Mangoceuticals shares in Q4 2025, an estimated $483K.
  • Mangoceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4004 holding.
  • Vanguard Group first reported a position in Mangoceuticals in Q2 2025 and has held it in 3 quarters since.
  • Vanguard Group's Mangoceuticals position peaked at $420K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.